SEP 7, 2026 · JOURNAL ARTICLE
IL-10’s contextual role in cytotoxic antitumor immunity: evidence, controversies, and therapeutic translation
Frontiers in Immunology
This is a narrative review synthesizing mechanistic evidence and preclinical models with conflicting human data, proposing a framework rather than reporting a new empirical result; the only completed Phase 3 trial (pegilodecakin) failed its primary endpoint.
Reported
Clinical trial status of IL-10-ba…Pegilodecakin: only IL-10-based agent to co…